Clene (CLNN)
(Delayed Data from NSDQ)
$5.00 USD
-0.19 (-3.66%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.96 -0.04 (-0.80%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CLNN 5.00 -0.19(-3.66%)
Will CLNN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLNN
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet
Wall Street Analysts Believe Clene (CLNN) Could Rally 976.32%: Here's is How to Trade
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Other News for CLNN
Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)
Clene’s CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy Recommendation
Buy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene’s CNM-Au8
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data
Clene announces it will meet in-person with FDA to discuss CNM-Au8